United Immunity, Co., Ltd., a Japanese biotech company developing a Myeloid Targeting Platform™, announced today that the Japanese Patent Office has granted a fundamental patent (PCT/JP2024/009979, JP2024-517587) related to its PEG-Free pullulan-based lipid nanoparticle (P-LNP). The patent protects various compositions of P-LNP that actively and selectively target nucleic acids such as mRNA to dendritic cells and macrophages through the binding of the DC-SIGN receptor. P-LNP is ideal for vaccines against infectious diseases and cancer, but also has the potential of modulating myeloid cells involved in fibrosis, inflammation, obesity, insulin-resistance and autoimmune diseases.
"We will continue to protect our platform technology on a global basis, with the aim of obtaining patent rights in the US, Europe and other countries as soon as possible" said Masato Kishida, President of United Immunity. PDF